Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

By Alimat Aliyeva Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it pla ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics originally established Samsung Bioepis as a joint venture with U.S. pharmaceutical company Biogen Inc. in ...

Samsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines ...

The US biotech – currently in the throes of a major restructuring drive under new ... of a potential sale to longstanding partner Samsung Bioepis and a bid from Indian drugmaker Intas.

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...